Research ArticleOriginal Article
Open Access

Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty

Hala H. Swaiss, Nahla M. Khawaja, Oraib H. Farahid, Anwar M. Batieha and Kamel M. Ajlouni
Saudi Medical Journal November 2017, 38 (11) 1101-1107; DOI: https://doi.org/10.15537/smj.2017.11.21187

References

  1. ↵
    1. Fahmy JL,
    2. Kaminsky CK,
    3. Kaufman F,
    4. Nelson Jr MD,
    5. Parisi MT
    (2000) The radiological approach to precocious puberty. Br J Radiol 73:560–567.
    OpenUrlAbstract
  2. ↵
    1. Dixon JR,
    2. Ahmed SF
    (2007) Precocious puberty. Pediatrics and Child Health 17:343–348.
    OpenUrl
  3. ↵
    1. Cutler GB
    (1997) The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 61:141–144.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Juul A
    (2001) The effects of estrogens on linear bone growth. Human Reproduction Update 7:303–313.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Sonis WA,
    2. Comite F,
    3. Blue J,
    4. Pescovitz OH,
    5. Rahn CW,
    6. Hench KD,
    7. et al.
    (1985) Behavior problems and social competence in girls with true precocious puberty. J Pediatr 106:156–160.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Sorgo W,
    2. Kiraly E,
    3. Homoki J,
    4. Heinze E,
    5. Teller WM,
    6. Bierich JR,
    7. et al.
    (1987) The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol 115:44–56.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Carel JC,
    2. Eugster EA,
    3. Rogol A,
    4. Ghizzoni L,
    5. Palmert MR
    (2009) Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123:e752–762.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Heger S,
    2. Müller M,
    3. Ranke M,
    4. Schwarz HP,
    5. Waldhauser F,
    6. Partsch CJ,
    7. et al.
    (2006) Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 254:217–220.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Larsen PR,
    2. Kronenberg HM,
    3. Melmed S,
    4. Polansky KS
    (2003) Williams textbook of endocrinology, physiology, Puberty: ontogenety, neuroendocrinology, physiology and disorder (Saunders, Philadilphia (PA)), 10th ed, pp 1115–1239.
  10. ↵
    1. Lahlou N,
    2. Carel JC,
    3. Chaussain JL,
    4. Roger M
    (2000) Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 13:723–738.
    OpenUrlCrossRefWeb of Science
  11. ↵
    1. Schoevaart CE,
    2. Drop SL,
    3. Otten BJ,
    4. Slijper FM,
    5. Degenhart HJ
    (1990) Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm Res 34:197–203.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Taher BM,
    2. Ajlouni HK,
    3. Hamamy HA,
    4. Shegem NS,
    5. Madanat AY,
    6. Ajlouni KM
    (2004) Precocious puberty at an endocrine center in Jordan. Eur J Clin Invest 34:599–604.
    OpenUrlPubMed
  13. ↵
    1. Blethen SL,
    2. Baptista J,
    3. Kuntze J,
    4. Foley T,
    5. LaFranchi S,
    6. Johanson A
    (1997) Genentech Growth Study Group. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab 82:418–420.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Cameron N
    (1986) The methods of auxological anthropometry. Human growth 31:3–46.
    OpenUrl
  15. ↵
    1. Tanner JM
    (1962) Growth and adolescence (Blackwell Publishers, Oxford (UK)), 2nd ed.
  16. ↵
    1. Greulich WW,
    2. Pyle EI
    (1966) Radiographic atlas of skeletal development of the hand and wrist (Stanford University Press, Stanford (CA)), 2nd ed.
  17. ↵
    1. Bayley N,
    2. Pinneau SR
    (1952) Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 40:423–441.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Sorva R,
    2. Tolppanen EM,
    3. Lankinen S,
    4. Perheentupa J
    (1989) Growth evaluation: parent and child specific height standards. Arch Dis Child 64:1483–1487.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Roede MJ
    (1985) Growth diagrams 1980. Netherlands third national survey. Tijdsch Soc Gezondh 63:1–34.
    OpenUrl
  20. ↵
    1. Guaraldi F,
    2. Beccuti G,
    3. Gori D,
    4. Ghizzoni L
    (2016) Management of endocrine disease: Long-term outcomes of the treatment of central precocious puberty. European Journal of Endocrinology 174:R79–87.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Arrigo T,
    2. Cisternino M,
    3. Galluzzi F,
    4. Bertelloni S,
    5. Pasquino AM,
    6. Antoniazzi F,
    7. et al.
    (1999) Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 141:140–144.
    OpenUrlAbstract
  22. ↵
    1. Kletter GB,
    2. Kelch RP
    (1994) Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 79:331–334.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Brauner R,
    2. Adan L,
    3. Malandry F,
    4. Zantleifer D
    (1994) Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 79:415–420.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Bouvattier C,
    2. Coste J,
    3. Rodrigue D,
    4. Teinturier C,
    5. Carel JC,
    6. Chaussain JL,
    7. et al.
    (1999) Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. TJ Clin Endocrinol Metab 84:3575–3578.
    OpenUrl
  25. ↵
    1. Carel JC,
    2. Roger M,
    3. Ispas S,
    4. Tondu F,
    5. Lahlou N,
    6. Blumberg J,
    7. et al.
    (1999) French study group of Decapeptyl in Precocious Puberty. Final height after long-term treatment with triptorelin slow release for central precocious puberty: the importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 84:1973–1978.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Sigurjonsdottir TJ,
    2. Hayles AB
    (1968) Precocious puberty: a report of 96 cases. Am J Dis Child 115:309–321.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Paul DA,
    2. Conte FA,
    3. Grumbach MM,
    4. Kaplan SL
    (1995) The long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of fewer than 5 years. J Clin Endocrinol Metab 80:546–551.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Pasquino AM,
    2. Pucarelli I,
    3. Accardo F,
    4. Demiraj V,
    5. Segni M,
    6. Di Nardo R
    (2008) Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 93:190–195.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Stasiowska B,
    2. Vannelli S,
    3. Benso L
    (1994) Final height in sexually precocious girls after therapy with an intranasal analog of gonadotrophin-releasing hormone (buserelin). Hormone Research in Paediatrics 42:81–85.
    OpenUrl
  30. ↵
    1. Cassio A,
    2. Cacciari E,
    3. Balsamo A,
    4. Bal M,
    5. Tassinari D
    (1999) Randomised trial of LHRH analog treatment on final height in girls with the onset of puberty aged 7.5–8.5 years. Archives of Disease in Childhood 81:329–332.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lazar L,
    2. Padoa A,
    3. Phillip M
    (2007) Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 92:3483–3489.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Yanovski JA,
    2. Rose SR,
    3. Municchi G,
    4. Pescovitz OH,
    5. Hill SC,
    6. Cassorla FG,
    7. et al.
    (2003) Treatment with a luteinizing hormone–releasing hormone agonist in adolescents with short stature. N Engl J Med 348:908–917.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Galluzzi F,
    2. Salti R,
    3. Bindi G,
    4. Pasquini E,
    5. Cauza C
    (1998) Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analog therapy. Acta Paediatrica 87:521–527.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Bertelloni S,
    2. Baroncelli GI,
    3. Sorrentino MC,
    4. Perri G,
    5. Saggese G
    (1998) Effect of central precocious puberty and gonadotropin-releasing hormone analog treatment on peak bone mass and final height in females. Eur J Pediatr 157:363–367.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Adan L,
    2. Chemaitilly W,
    3. Trivin C,
    4. Brauner R
    (2002) Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol 56:297–302.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Mul D,
    2. Bertelloni S,
    3. Carel JC,
    4. Saggese G,
    5. Chaussain JL,
    6. Oostdijk W
    (2002) Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 58:1–7.
    OpenUrlPubMedWeb of Science
  37. ↵
    1. Bajpai A,
    2. Sharma J,
    3. Kabra M,
    4. Gupta AK,
    5. Menon PS
    (2002) Long-acting GnRH analog triptorelin therapy in central isosexual precocious puberty. Indian Pediatrics 39:633–639.
    OpenUrlPubMed
  38. ↵
    1. Liang Y,
    2. Wei H,
    3. Li J,
    4. Hou L,
    5. Zhang J,
    6. Wu W,
    7. et al.
    (2015) Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab 28:839–846.
    OpenUrl
  39. ↵
    1. Kauli R,
    2. Galatzer A,
    3. Kornreich L,
    4. Lazar L,
    5. Pertzelan A,
    6. Laron Z
    (1997) The final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analog. Horm Res 47:54–61.
    OpenUrlPubMedWeb of Science
    1. Guaraldi F,
    2. Beccuti G,
    3. Gori D,
    4. Ghizzoni L
    (2016) Management of endocrine disease: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 174:R79–87.
    OpenUrlAbstract/FREE Full Text
    1. Kumar M,
    2. Mukhopadhyay S,
    3. Dutta D
    (2015) Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: an Indian perspective. Indian J Endocrinol Metab 19:228.
    OpenUrl
    1. Kim EY
    (2015) Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty. Korean J Pediatr 58:1–7.
    OpenUrl
  43. ↵
    1. Jung MK,
    2. Song KC,
    3. Kwon AR,
    4. Chae HW,
    5. Kim DH,
    6. Kim HS
    (2014) Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab 19:214–219.
    OpenUrl
  44. ↵
    1. van Gool SA,
    2. Kamp GA,
    3. Visser-van Balen H,
    4. Mul D,
    5. Waelkens JJ,
    6. Jansen M,
    7. et al.
    (2007) Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 92:1402–1408.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section